HR Execs on the Move

Readcoor

www.readcoor.com

 
ReadCoor is leading the next generation of `omics` by delivering the first panomic spatial sequencing platform to the global audience of researchers, clinicians, pharma and diagnostics companies, and ultimately patients. It is accomplishing this with a fundamental new technology called FISSEQ which simultaneously enables integration of high throughput sequencing, morphometric analysis, cellular location and three dimensional spatial imaging. This uniquely powerful tool is the first and only implementation of `In-situ Sequencing` and will revolutionize the next phase in understanding the transcriptome, introducing vast new opportunities for important and meaningful clinical insight. ReadCoor will fulfill the mission with a comprehensive ...
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.readcoor.com
  • 196 Boston Avenue Suite 1000
    Medford, MA USA 02155
  • Phone: 781.219.3575

Executives

Name Title Contact Details
Lori Johnson
Chief Human Resources Officer Profile

Similar Companies

Purigen Biosystems

Purigen Biosystems transformative platform provides a hands-free solution for extracting, enriching and quantifying DNA and RNA from biological samples.

Boston Biomedical Research Institute

The Boston Biomedical Research Institute (BBRI) is dedicated to basic biomedical research to promote the understanding, treatment and prevention of specific human diseases. The areas of investigation concern the structure and function of muscle proteins,

Pharma BioSource Inc

Pharma BioSource Inc is a Blue Bell, PA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Cerulean

The Cerulean team is committed to improving treatment for people living with cancer. We apply our Dynamic Tumor Targeting Platform to create a portfolio of NDCs designed to selectively attack tumor cells, reduce toxicity by sparing the body’s normal cells, and enable therapeutic combinations. Our first platform-generated candidate, CRLX101, is in multiple clinical trials in combination with other cancer treatments, all of which aim to unlock the power of combination therapy. Our second platform-generated candidate, CRLX301, is in a Phase 1/2a clinical trial.